The Dermatology Digest
AUGUST 14, 2024
The U.S. Food and Drug Administration (FDA) has cleared Candela’s Matrix system for the percutaneous treatment of facial wrinkles in patients with Fitzpatrick Skin Types (FST) I-IV using its Matrix Pro RF microneedling applicator. The applicator was previously FDA-cleared for use in general dermatological procedures involving hemostasis and electrocoagulation.
Dermatology Times
AUGUST 14, 2024
Myron Czuczman, MD, of Citius Pharmaceuticals recently shared perspectives on the role and potential of Lymphir in CTCL.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Salon Today
AUGUST 14, 2024
From operations to finances and growth strategies to culture, a comprehensive list of strategies to maximize your salon profitability.
Dermatology Times
AUGUST 14, 2024
Despite high accuracy scores, the study found AI models often produce overly complex explanations, making them less effective for patient education.
Skin Inc
AUGUST 14, 2024
The expansive new facility near the Willowbrook Mall is designed to elevate vocational education for New Jersey’s aspiring beauty professionals.
Dermatology Times
AUGUST 14, 2024
The new indication adds to existing clearances for hemostasis and electrocoagulation.
Esthetician Leadership Today brings together the best content for skin care professionals from the widest variety of industry thought leaders.
Lipgloss and Aftershave
AUGUST 14, 2024
Katrina Yokoyama owns the award-winning spa, Trin Spa Skin and Wellness. Katrina Yokoyama’s philosophy is to customize every treatment for clients so that she can achieve maximum results. In order to implement her treatment philosophy she selected a skin care brand that offered an immense amount of both in-treatment and home care options. Katrina won awards from The Skin Games in 2017 and from Best of Central California for People’s Choice in 2023.
Dermatology Times
AUGUST 14, 2024
The overall reduction of tumor size in all lesions treated in part 2 was approximately 86%.
US Dermatologt Partners
AUGUST 14, 2024
Tyler, Texas – U.S. Dermatology Partners is pleased to welcome Certified Physician Assistant Rebecca Ellspermann, PA-C to their Tyler, Texas office. U.S. Dermatology Partners Welcomes Rebecca Ellspermann, MPAS, PA-C to their Tyler, Texas Office Rebecca Ellspermann earned her Bachelor of Arts in Biology from The University of Texas at Austin. She then earned her Master of Physician Assistant Studies from The University of Texas Medical Branch in Galveston.
Dermatology Times
AUGUST 14, 2024
The trial revealed that 40% of patients on izokibep achieved HiSCR75 by week 16, a notable improvement over the 20% on placebo.
The Dermatology Digest
AUGUST 14, 2024
Neutrogena is debuting Neutrogena Collagen Bank SPF 30 Moisturizer and the Neutrogena Collagen Bank Moisturizer. Both products contain patented micro-peptide technology to penetrate into the skin’s deeper layers. Formulated with ingredients specifically designed to “bank” collagen, the moisturizers preserve defend and support skin’s natural collagen stores.
Dermatology Times
AUGUST 14, 2024
Omer Ibrahim, MD, discusses the nuances of aesthetic procedures for patients with skin of color and the importance of tailored treatments, safety, and improved clinician education.
Starpil Wax
AUGUST 14, 2024
In this economy, many people are turning to DIY approaches to hair removal to save money and time. If you’re considering trying bikini waxing out on your own, you’re not alone! There are many ways to wax the bikini line safely and completely by yourself so you can enjoy hair-free results without breaking the bank. Table of Contents Understanding Bikini Wax Styles Step-by-Step Bikini Line Waxing Tutorial Essential Bikini Line Waxing Aftercare Final Thoughts This guide will walk you through the b
The Dermatology Digest
AUGUST 14, 2024
Verrica Pharmaceuticals Inc.’s VP-315 is showing promise in the treatment of basal cell carcinoma, according to Part 2 of its Phase 2 clinical trial. VP-315 is a potential first-in-class oncolytic peptide immunotherapy designed to be administered directly into a tumor to induce immunogenic cell death. All patients treated with VP-315 had a reduction in tumor size with an overall reduction in tumor size of all lesions treated in Part 2 of approximately 86%, an approximately 51% of lesions treated
Expert insights. Personalized for you.
74 
Let's personalize your content